Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
-
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
-
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
-
Longeveron to Present at the Emerging Growth Virtual Conference
-
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
-
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
-
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
-
Longeveron announces planned transitions on its Board of Directors.
-
Longeveron to report Q1 2024 financial results on May 14, 2024.
-
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.